JPRN-UMIN000007838已完成未知
To investigate the efficacy and safety of Bortezomib and Lenalidomide as induction, consolidation and maintenance therapy for untreated multiple myeloma patients eligible for autologous stem cell transplantation. - Kanshinetsu MMG-001
Kanshinetsu Multiple Myeloma Group0 个研究点目标入组 47 人开始时间: 2012年4月27日最近更新:
适应症
试验速览
- 阶段
- 未知
- 状态
- 已完成
- 发起方
- 入组人数
- 47
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 20years-old 至 65years-old（—）
- 性别
- All
入选标准
- 未提供
排除标准
- •1. Non-secretory MM and plasmacell leukemia. 2. Patients HIV-HBs-and HCV-positive 3. Severe hepatic dysfunction, severe renal failure, severe cardiac dysfunction, severe pulmonary dysfunction, uncontrolled diabetes, uncontrolled hypertension, and uncontrolled infection. 4. Patients with a history of active malignancy during the past 5 years. 5. Patients with psychiatric disorders such as schizophrenia etc. 6. Pregnant women, pre-menopausal women, and lactating women. 7. History of hypersensitivity to mannitol or boron. 8. Patient was suspected pneumonia(Interstitial pneumonia). Consult a respiratory specialist if necessary 9. Those who are considered as inappropriate to register by attending physicians.
研究者
相似试验
已完成
不适用
To investigate the efficacy and safety of bortezomib as maintenance therapy for untreated multiple myeloma patients ineligible for autologous stem cell transplantatioMultiple myelomaJPRN-UMIN000007880Kanshinetsu Multiple Myeloma Group35
已完成
不适用
Clinical trial to evaluate the safety of Bortezomib combined with chemotherapy in children with refractory childhood acute lymphoblastic leukemiarefractory childhood acute lymphoblastic leukemiaJPRN-UMIN000010566Department of Pediatrics, Hokkaido University Hospital6
进行中（未招募）
1 期
EFFICACY AND SAFETY OF THE COMBINATION OF BORTEZOMIB, LENALIDOMIDE AND DEXAMETHASONE IN NEWLY DIAGNOSED MULTIPLE MYELOMA PATIENTSMultiple myelomaEUCTR2019-002626-67-ESInstitut Català d'Oncologia360
招募中
不适用
Pharmacokinetics and clinical outcomes of bortezomib in patients with newly diagnosed myelomamultiple myelomaJPRN-UMIN000006257Division of Hematology, Department of Medicine, Keio University, School of Meidicine40
进行中（未招募）
1 期
A randomized phase III study to compare Bortezomib, Melphalan, Prednisone (VMP) with High Dose Melphalan followed by Bortezomib, Lenalidomide, Dexamethasone (VRD) consolidation and Lenalidomide maintenance in patients with newly diagnosed multiple myeloma.Multiple MyelomaEUCTR2009-017903-28-SKHOVON Foundation1,500